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Background: Novel vaccine strategies are required to provide protective immunity in tuberculosis (TB)
and prevent development of active disease. We investigated the safety and immunogenicity of a novel
TB vaccine candidate, H4:IC31 (AERAS-404) that is composed of a fusion protein of M. tuberculosis anti-
gens Ag85B and TB10.4 combined with an IC31 adjuvant.
Methods: BCG-vaccinated healthy subjects were immunized with various antigen (5, 15, 50, 150 lg) and
adjuvant (0, 100, 500 nmol) doses of the H4:IC31 vaccine (n = 106) or placebo (n = 18) in two randomized,
double-blind, placebo-controlled phase I studies conducted in a low TB endemic setting in Sweden and
Finland. The subjects were followed for adverse events and CD4+ T cell responses.
Results: H4:IC31 vaccination was well tolerated with a safety profile consisting of mostly mild to mod-
erate self-limited injection site pain, myalgia, arthralgia, fever and post-vaccination inflammatory reac-
tion at the screening tuberculin skin test injection site. The H4:IC31 vaccine elicited antigen-specific
CD4+ T cell proliferation and cytokine production that persisted 18 weeks after the last vaccination.
CD4+ T cell expansion, IFN-c production and multifunctional CD4+ Th1 responses were most prominent
after two doses of H4:IC31 containing 5, 15, or 50 lg of H4 in combination with the 500 nmol IC31 adju-
vant dose.
Conclusions: The novel TB vaccine candidate, H4:IC31, demonstrated an acceptable safety profile and was
immunogenic, capable of triggering multifunctional CD4+ T cell responses in previously BCG-vaccinated
healthy individuals. These dose-escalation trials provided evidence that the optimal antigen-adjuvant
dose combinations are 5, 15, or 50 lg of H4 and 500 nmol of IC31.
Conclusions: Trial registration: ClinicalTrials.gov, NCT02066428 and NCT02074956.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
WHO has declared tuberculosis (TB) as a global health emer-
gency and despite socioeconomic improvement, TB continues to
cause a considerable number of deaths. A preventive TB vaccine
could reduce the spread and severity of TB disease significantly.
The bacillus Calmette-Guérin (BCG) vaccine provides incomplete
protection against pulmonary TB and a boost with BCG does not
consistently provide additional protection [1,2]. However, new-
born BCG vaccine prevention is still a major global strategy for
M. Norrby et al. / Vaccine 35 (2017) 1652–1661 1653the control of TB, which underlines the importance of developing
an improved TB vaccine that would more effectively boost BCG.
H4:IC31 (AERAS-404) is an investigational vaccine that is com-
posed of two active components: the H4 antigen which is a fusion
protein created from two Mycobacterium tuberculosis (Mtb)-
antigens, antigen 85B (Ag85B) and TB10.4, and an immunological
adjuvant called IC31. The rationale of the H4:IC31 vaccine is that
presentation of Mtb-specific antigens in this setting could augment
T cell immunity induced by BCG and thus improve protection
against TB. Ag85B is a 30 kDa mycolyl transferase protein [3,4] that
has previously been demonstrated to induce substantial protective
immunity against aerosol challenge with the highly virulent Mtb
Erdman strain in guinea pigs [5]. TB10.4 is one of three members
of the very similar early secretory antigenic target (ESAT)-6 group
of proteins found in Mtb culture supernatants [6]. TB10.4 has been
shown to induce larger and broader immune responses in T cells
isolated from TB patients compared to BCG-vaccinated and non-
vaccinated donors [7]. Immunization of mice with a fusion protein
of TB10.4 and Ag85B has been shown to induce a significant syner-
gistic protective effect against subsequent aerosol challenge with
Mtb [8]. Similarly, Ag85B and ESAT-6 (H1 antigen) induced potent
and long-lived effector T cell responses in naïve volunteers when
administrated in the presence of the IC31 adjuvant [9,10]. The pro-
prietary IC31 adjuvant (Valneva, Vienna, Austria) is a combination
of a leucine-rich peptide, KLK, and a synthetic oligonucleotide,
ODN1a. KLK enhances the uptake of antigens into antigen-
presenting cells and therefore improves the immune response to
peptide antigens. ODN1a is a synthetic bacterial DNA analogue that
resembles a CpG motif that will promote a Th1 response and the
production of IFN-c and IL-2, which are considered to play essen-
tial roles in protection against TB [11]. In addition, the IC31 adju-
vant enhances the production of both IFN-c and humoral
responses via the TLR9 signaling pathway [12,13].
It has been demonstrated in animal studies that H4:IC31 boosts
BCG immunity and provides greater protection against develop-
ment of TB disease than BCG alone [14–16]. Therefore we aimed
to test the safety and immunogenicity of the H4:IC31 vaccine in
a prime-boost vaccination strategy in healthy, previously BCG-
vaccinated individuals who received different antigen-adjuvant
dose combinations of the study vaccine, in two phase I clinical tri-
als performed in Sweden (Aeras protocol C-005-404) and Finland
(Aeras protocol C-006-404), respectively. We designed the first-
in-human C-005-404 study to optimize the dose of the IC31 adju-
vant with a fixed dose of H4 antigen, and the subsequent C-006-
404 study to optimize the dose of H4 antigen with a fixed dose
of IC31 adjuvant.
2. Materials and methods
2.1. Subjects and study design
We conducted two phase I randomized, double-blind, placebo-
controlled studies at the Department of Infectious Diseases,Table 1
A dose matrix of the H4 and IC31 dose combinations administered to the study subjects i
One vaccination Two vaccinatio
Day 0 Day 0 and 56
H4 dose 50 lg 150 lg 5 lg
No adjuvant 8 8 –
100 nmol IC31 8 – 9
500 nmol IC31 8 – 8
Placebo – 18c
a A total of 124 participants were included in the two trials.
b Two doses of 50 lg H4 in 500 nmol IC31 were administered to 8 participants in ea
c A total of 18 participants received two placebo vaccinations in the two trials.Karolinska University Hospital Huddinge in Stockholm, Sweden
(Aeras protocol C-005-404; ClinicalTrials.gov ID NCT02066428)
and at the Vaccine Research Center, University of Tampere in Fin-
land (Aeras protocol C-006-404; ClinicalTrials.gov ID
NCT02074956). Inclusion criteria were: previously BCG-
vaccinated (P5 years), males or females (females required to be
sterile for C-005-404), age 18-50 years, HIV-uninfected, good
health based on medical history, normal BMI (19–33), no evidence
of an ongoing TB infection and written informed consent com-
pleted. Both studies employed dose-escalation, with increasing
amounts of the H4 antigen (5, 15, 50 or 150 lg) administered in
the presence of increasing amounts of the IC31 adjuvant (0, 100
or 500 nmol) (Table 1). Statens Serum Institut (SSI) in Copenhagen,
Denmark manufactured the H4 fusion protein and the IC31 adju-
vant. Formulation buffer was used as placebo control. Subjects
received vaccinations via intramuscular injection with H4:IC31 or
placebo on study days 0 and 56. Treatment assignments were
based on a randomly-generated sequence of subject identification
numbers on a randomization schedule, provided by an unblinded
statistician to the study pharmacist in a sealed tamper-evident
envelope.
Protocol C-005-404 was approved by the Regional Ethical
Review Board (Stockholm) and the Medicinal Product Agency in
Sweden, while protocol C-006-404 was approved by the Hospital
District of Pirkanmaa Ethics Committee (Tampere) and the
National Agency for Medicines in Finland (Finnish Medicines
Agency). The studies were conducted in accordance with the Dec-
laration of Helsinki and applicable local regulations for conducting
clinical trials on medicinal products in humans.
2.2. Adverse events
Safety of the H4:IC31 vaccine treatment regimens were based
on the induction of adverse events (AEs) that represented both
clinical and laboratory evaluations (see Supplementary materials).
AE severity was graded according to the US Food and Drug Admin-
istration (FDA) toxicity tables for Healthy Adult and Adolescent
Volunteers Enrolled in Preventive Vaccine Clinical Trials [17] using
criteria that were pre-specified in the study protocols provided by
the sponsor i.e. Areas. We recorded solicited and unsolicited AEs
during the first 28 days after each vaccination i.e. study days
0–28 and 56–84, and serious AEs (SAEs) during the 6 month study
period.
2.3. Immunogenicity testing
Peripheral blood mononuclear cells (PBMC) were isolated from
blood collected on study days 0, 7, 14, 28, 56, 63, 70, 84, and 182
for intracellular cytokine staining (ICS) performed at Aeras [18]
and on study days 0, 56, 84, and 182 for assessment of Mtb-
specific IFN-c production using ELISpot performed at Leiden
University Medical Center according to Protocol S2 previously
described by Dr. Steven Smith et al. [19] (see Supplementaryn the C-005-404 and C-006-404 trials.a
ns
15 lg 50 lg 150 lg Total (n = 124)
– 8 – 24
9 8 – 34
8 16b 8 48
18
ch of the C-005-404 and C-006-404 trials.
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days 0, 7, 28, 63, 84, and 182 for Flow-cytometric Assay for Specific
Cell-mediated Immune-response in Activated whole blood assay
(FASCIA performed at the Public Health Agency of Sweden)
[20,21] (see Supplementary materials). Subjects were screened
for ongoing TB infection using QuantiFERON and the tuberculin
skin test (TST) (see Supplementary materials).
2.4. Data analysis
The sample size for each trial was selected as adequate for an
initial review of the safety profile of H4:IC31. Basic descriptive
analysis was performed for each treatment regimen to examine
AEs and immune responses measured by ICS, IFN-c ELISpot and
FASCIA. Comparisons between treatment regimens for ICS and
IFN-c ELISpot immune responses were conducted by area under
the curve (AUC) analyses. The trapezoidal rule was used to calcu-
late the AUC for each subject, with negative and positive peaks rel-
ative to each subject’s baseline data included to calculate net peak
area. Overall p-values for median AUC among treatment regimens
were obtained using the Kruskal-Wallis test. Pairwise comparisons
of median AUC between treatment regimens were conducted using
a Mann-Whitney exact test. The Holm method was used to correct
for multiple comparisons.
3. Results
3.1. Enrollment and demography
We screened a total of 206 healthy BCG-vaccinated individuals
for eligibility, enrolled 125 individuals and randomized them into
the different intervention groups as described in Fig. 1. Demo-
graphic characteristics were generally similar across treatment
regimens within each trial (Supplementary Tables 1A and 1B). In
the C-005-404 study, all 64 randomized subjects received the
study day 0 vaccination and all subjects completed the study. In
the C-006-404 study, 60 of 61 randomized subjects received the
study day 0 vaccination and all subjects except two completed
the study.
3.2. Adverse events (AEs)
The majority (83%) of subjects across both studies had AEs
graded as mild or moderate (Tables 2a and 2b), and three (2%) sub-
jects had no AEs. n = 18 (15%) subjects had at least one severe AE
(Tables 2a and 2b) of which four were considered related to the
study vaccine: fever (150/0 one dose regimen), increased protein
in urine (15/100 two dose regimen), TST site reaction (50/100
two dose regimen, discussed below), and increased international
normalized ratio (INR) (150/500 two dose regimen). The overall
incidence and severity of the AEs were not different comparing
H4:IC31 vaccinations with placebo (Tables 2a and 2b). Four SAEs
were reported, none of which was considered related to study vac-
cination: mental status changes (50/0 one dose regimen); mesen-
teric lymphadenitis (50/500 two dose regimen); ileus (50/500
two dose regimen); and subdural hemorrhage (placebo).
Most subjects had at least one solicited or unsolicited AE
recorded (Tables 3a and 3b). Among solicited AEs, myalgia, arthral-
gia, and fever (pyrexia) occurred at a higher frequency in subjects
who received the H4:IC31 vaccine compared to placebo in the C-
005-404 study (Table 3a). All cases of fever occurred within 1–
2 days of the first vaccination, resolved within 2–3 days and did
not recur after the second study vaccination. There was a trend
towards an increased frequency of some systemic solicited AEs at
the 150 lg H4 dose level, particularly when combined with
500 nmol IC31 (Tables 3a and 3b). Pain at the injection site wasincreased in subjects who received H4 together with the IC31 adju-
vant, as compared to placebo (Tables 3a and 3b) or H4 alone
(Table 3a). For other solicited AEs and all unsolicited AEs (except
TST site reaction, discussed below), the AE profiles were similar
across the H4:IC31 and placebo treatment regimens (Tables 3a
and 3b). For each regimen, the AE profiles identified after the sec-
ond vaccination were similar to those detected after the first vac-
cination (data not shown). See Supplementary Tables 2A and 2B,
for a complete list of AEs in the trials.
In the C-005-404 study, some degree of post-study vaccination
inflammation occurred at the screening TST injection site in 14 of
the first 21 (66.7%) TST-negative subjects who received the H4:
IC31 vaccine. Among these 14 subjects, TST site reactions were eli-
cited by the H4 antigen alone (11/14, 78.6%) or H4 combined with
a low dose (100 nm) of IC31 adjuvant (3/14, 21.4%) (Table 3a). One
subject (50/100 two dose regimen) experienced a severe reaction
at the TST site with onset the day of the first study vaccine admin-
istration. The subject had no screening TST reactivity or a reaction
at the vaccine site (Supplementary materials).
3.3. Immunogenicity
We considered detection of antigen-specific T cell proliferation
and cytokine production (single- or co-expression of IFN-c, TNF-a
and/or IL-2) in PBMC samples in response to vaccine-antigens as
potentially important correlates of immune protection. T cell
expansion in each of the H4:IC31 one dose regimens was limited
to the CD4+ T cell subset that responded to the vaccine antigen
Ag85B in some subjects, although these responses were not sus-
tained (Fig. 2A, Supplementary Table 3A). In each of the H4:IC31
two dose regimens, the study vaccine induced Ag85B-specific but
also TB10.4-specific CD4+ T cell responses, with a boosting effect
seen after administration of the second dose (Fig. 2B and Fig. 2C,
Supplementary Tables 3A and 3B). These responses peaked at 2
and 4 weeks after the second vaccination and were sustained up
to 18 weeks after the last vaccination (Fig. 2B and Fig. 2C). The
most strong and long-lived median CD4+ T cell responses com-
pared to placebo were seen after stimulation with Ag85B in the
5/500 (p < 0.01), 15/500, and 50/500 (p < 0.01) two dose regimens,
while the proportion of antigen-specific CD4+ T cells was lower
using the higher H4 dose 150/500 (Fig. 2B and Fig. 2C, Supplemen-
tary Tables 3A, 3B and 4B). These results were supported by the
whole blood FASCIA assay, where the two dose 50/500 treatment
was shown to be the superior regimen that induced significant
expansion of Ag85B-specific CD4+ T cells (p = 0.02) (Supplementary
Fig. 1A) and CD8aa+ T cells (p < 0.001) (Supplementary Fig. 1B)
compared to the two dose placebo regimen.
IFN-c ELISpot responses were elevated in response to both
Ag85B and TB10.4, but only for the two dose regimens together
with the IC31 adjuvant (Fig. 3A and Fig. 3B). A boosting effect
was seen after the second H4:IC31 dose, particularly in the pres-
ence of the higher IC31 adjuvant dose, and these responses were
sustained up to 18 weeks after the last vaccination
(Fig. 3B and Fig. 3C). Similar to antigen-specific CD4+ T cell expan-
sion (Fig. 2B and Fig. 2C), the most potent IFN-c ELISpot responses
were seen in the 5/500 (p < 0.01), 15/500 (p = 0.02) and the 50/500
(p = 0.02) two dose regimens compared to placebo
(Fig. 3B and Fig. 3C, Supplementary Tables 4C and 4D). ICS analysis
of Ag85B-specific CD4+ T cells at 4 weeks after the second vaccina-
tion (study day 84) confirmed that only the two dose treatment
regimens efficiently induced cytokine producing cells (Fig. 4A–C)
These primarily included bi-functional IL-2/TNF-a producing and
multifunctional IFN-c/IL-2/TNF-a producing T cells and, to a lesser
extent, mono-functional T cells (Fig. 4B and Fig. 4C). See Supple-
mentary Tables 4A–4D, for complete analyses on the statistical dif-
ferences between the vaccine groups.
Assessed for eligibility 
(n=200) Excluded  (n=75) 
Not meeting inclusion criteria (n=66) 
Abnormal laboratory value (n=22)
Posive/indeterminate QFT/PPD (n=20)
Other (n=24)
Declined to participate (n=9) 
Analysed  (n=18) 
Excluded from analysis (n=0)
Lost to follow-up (n=0) 
Discontinued intervention (n=0)
Allocated to placebo (n=18) 
 Received allocated intervention (n=18) 
C-005-404                       C-006-404 
Group 1
Placebo: 2 doses (n=3)
Group 2
Placebo: 2 doses (n=3)
Group 3
Placebo: 2 doses (n=2)
Total Placebo (n=8)
Group 1
Placebo: 2 doses (n=2)
Group 2
Placebo: 2 doses (n=2)
Group 3
Placebo: 2 doses (n=2)
Group 4
Placebo: 2 doses (n=2)
Group 5
Placebo: 2 doses (n=2)
Total Placebo (n=10)
Did not receive allocated intervention (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=6) 
C-005-404            C-006-404 
reacvaon of Grave’s
disease, recorded as
hyperthyroidism (n=1)
withdrew consent (n=1)
laboratory values outside
reference range (n=4)
Discontinued from study (n=2)
C-005-404            C-006-404 
n=0 withdrew consent (n=1)
did not receive allocated
intervenon(n=1)
Allocated to H4:IC31 ( g H4/nmol IC31; n=107) 
 Received allocated intervention (n=106) 
C-005-404            C-006-404 
Group 1
50/0: 1 dose (n=8)*
50/0: 2 doses (n=8)
Group 2
50/100: 1 dose (n=8)*
50/100: 2 doses (n=8)
Group 3
50/500: 1 dose (n=8)*
50/500: 2 doses (n=8)
150/0: 1 dose (n=8)*
* Received placebo on
study day 56
Group 1
5/500: 2 doses (n=8)
Group 2
15/500: 2 doses (n=8)
Group 3
50/500: 2 doses (n=8)
Group 4
150/500: 2 doses (n=8)
Group 5
5/100: 2 doses (n=9)
15/100: 2 doses (n=9)
Did not receive allocated intervention (due to abnormal 
laboratory value [C-006-404]; n=1) 
Analysed  (n=106)
Excluded from analysis (n=1; subject that did not 
receive allocated intervention)
Allocation
Analysis
Follow Up
Randomized (n=125) 
C-005-404 C-006-404 
26/Nov/2007
11/Nov/2008
13/May/2008
15/Apr/2009
Enrollment
Fig. 1. Consort diagram of healthy previously BCG-vaccinated individuals, from screening to analysis. All subjects in C-005-404 completed the study. One C-005-404 subject
(150/0 one dose treatment regimen) with a history of Grave’s disease did not receive the study vaccine on study day 56 due to onset of hyperthyroidism. In the C-006-404
study, all subjects except two completed the study, one who retracted consent, and one who was not vaccinated and who was excluded from all analyses. Five C-006-404
subjects did not receive the study day 56 vaccination; one subject (150/500 two dose treatment regimen) withdrew consent and 4 subjects (one in each of the 5/100, 15/500,
50/500, and 150/500 two dose treatment regimens) had laboratory values outside the reference ranges of the local laboratory.
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These phase I vaccine trials were the first to explore a safe and
immunogenic dose and dosage range and to identify potential sideeffects of the H4:IC31 vaccine candidate in humans. Our principal
findings demonstrated that all vaccine doses and dosage combina-
tions tested were well tolerated in previously BCG-vaccinated
study subjects and most of the reported local and systemic AEs
Table 2a
Adverse events by highest severity for each subject: C-005-404.
H4:IC31 (lg H4/nmol IC31)
50/0 50/100 50/500 150/0
Placebo 1 Dose 2 Doses 1 Dose 2 Doses 1 Dose 2 Doses 1 Dose
(n = 8) (n = 8) (n = 8) (n = 8) (n = 8) (n = 8) (n = 8) (n = 8)
Severity n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Mild 3 (37.5) 4 (50.0) 2 (25.0) 4 (50.0) 2 (25.0) 1 (12.5) 2 (25.0) 1 (12.5)
Moderate 4 (50.0) 2 (25.0) 5 (62.5) 2 (25.0) 4 (50.0) 6 (75.0) 4 (50.0) 4 (50.0)
Severe 1 (12.5) 1 (12.5) 1 (12.5) 2 (25.0) 2 (25.0) 1 (12.5) 2 (25.0) 3 (37.5)
Table 2b
Adverse events by highest severity for each subject: C-006-404.
H4:IC31 (lg H4/nmol IC31)
Placebo 5/100 5/500 15/100 15/500 50/500 150/500
2 Doses 2 Doses 2 Doses 2 Doses 2 Doses 2 Doses 2 Doses
(n = 10) (n = 9) (n = 8) (n = 9) (n = 8) (n = 8) (n = 8)
Severity n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Mild 4 (40.0) 3 (33.3) 4 (50.0) 3 (33.3) 2 (25.5) 1 (12.5) –
Moderate 5 (50.0) 6 (66.7) 3 (37.5) 5 (55.6) 5 (62.5) 6 (75.0) 6 (75.0)
Severe – – 1 (12.5) 1 (11.1) 1 (12.5) – 2 (25.0)
Table 3a
Adverse events: C-005-404.
H4:IC31 (lg H4/nmol IC31)
50/0 50/100 50/500 150/0
Placebo 1 Dose 2 Doses 1 Dose 2 Doses 1 Dose 2 Doses 1 Dose
(n = 8) (n = 8) (n = 8) (n = 8) (n = 8) (n = 8) (n = 8) (n = 8)
MedDRA Preferred term n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Subjects with at least one solicited AE 6 (75.5) 6 (75.5) 5 (62.5) 7 (87.5) 6 (75.0) 7 (87.5) 7 (87.5) 8 (100.0)
Arthralgia – 1 (12.5) 2 (25.0) 3 (37.5) 2 (25.0) 4 (50.0) 1 (12.5) 4 (50.0)
Diarrhoea 1 (12.5) – – 1 (12.5) 1 (12.5) – – –
Fatigue 5 (62.5) 4 (50.0) 3 (37.5) 5 (62.5) 3 (37.5) 6 (75.0) 4 (50.0) 6 (75.0)
Headache 5 (62.5) 3 (37.5) 4 (50.0) 4 (50.0) 5 (62.5) 4 (50.0) 6 (75.0) 7 (87.5)
Injection site erythema 1 (12.5) 1 (12.5) – – – – 1 (12.5) –
Injection site pain 1 (12.5) – – 2 (25.0) 3 (37.5) 1 (12.5) 5 (62.5) 2 (25.0)
Injection site swelling 1 (12.5) – – – 1 (12.5) 1 (12.5) 3 (37.5) –
Myalgia 1 (12.5) 4 (50.0) 4 (50.0) 6 (75.0) 3 (37.5) 3 (37.5) 2 (25.0) 5 (62.5)
Pyrexia – – 2 (25.0) 2 (25.0) 1 (12.5) 4 (50.0) – 4 (50.0)
Subjects with at least one unsolicited AE 7 (87.5) 7 (87.5) 8 (100.0) 8 (100.0) 7 (87.5) 7 (87.5) 8 (100.0) 8 (100.0)
Aspartate aminotransferase increased – – 1 (12.5) – 1 (12.5) 3 (37.5) – 3 (37.5)
Blood creatine phosphokinase increased – – 2 (25.0) 1 (12.5) 1 (12.5) 5 (62.5) – 1 (12.5)
Blood pressure systolic increased 1 (12.5) – – 2 (25.0) 2 (25.0) – 2 (25.0) –
Haemoglobin decreased – 1 (12.5) – 1 (12.5) 1 (12.5) 1 (12.5) 3 (37.5) 1 (12.5)
Heart rate decreased 3 (37.5) – – – 6 (75.0) 3 (37.5) 5 (62.5) 2 (25.0)
Nasopharyngitis 2 (25.0) 1 (12.5) 2 (25.0) 1 (12.5) 1 (12.5) – 2 (25.0) 2 (25.0)
Nausea – 1 (12.5) 1 (12.5) 2 (25.0) 1 (12.5) 1 (12.5) – 1 (12.5)
Neutrophil count decreased 2 (25.0) – 2 (25.0) 3 (37.5) 2 (25.0) 1 (12.5) 2 (25.0) 3 (37.5)
Red blood cells urine – 2 (25.0) 1 (12.5) 2 (25.0) 1 (12.5) 3 (37.5) 1 (12.5) 1 (12.5)
TST site reactiona – 5 (62.5) 5 (62.5) 1 (12.5) 2 (25.0) – – 1 (12.5)
Note: Individual unsolicited AEs are shown for AEs reported in P10% of subjects across the combined H4:IC31 regimens. A full list of AEs is presented in Supplementary
Table 2A.
a Application site hypersensitivity or inflammatory reactions at the TST application site. Note that only the first 26 subjects randomized received a TST at screening.
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sistent antigen-specific CD4+ T cell responses in the peripheral cir-
culation including enhanced T cell proliferation and IFN-c
production, and also induction of multifunctional Th1 cells. Two
vaccinations with the H4 antigen using the lower doses ranging
from 5 to 50 lg (i.e. 5, 15, or 50 lg) in combination with the higher
dose (500 nmol) of the IC31 adjuvant induced the strongest T cell
responses to Ag85B, while the H4 antigen alone resulted in very
low T cell responses. This supports the fact that adjuvant proper-
ties are required for the induction of a strong and sustainedimmune response [22]. Importantly, a second vaccination with
H4:IC31 did not increase the frequency or severity of any reported
AEs as compared to a single vaccination.
The frequency and severity of AEs appeared to be independent
of the number (one or two) or dose (5, 15 or 50 lg) of H4 antigen in
the lower dose range, while an increased frequency of some sys-
temic solicited AEs was seen at the 150 lg H4 dose level. The AE
profiles among subjects who received the H4 antigen in the pres-
ence or absence of the IC31 adjuvant were similar, except for injec-
tion site pain, which suggested that the adjuvant did not contribute
Table 3b
Adverse events: C-006-404.
H4:IC31 (lg H4/nmol IC31)
Placebo 5/100 5/500 15/100 15/500 50/500 150/500
2 Doses 2 Doses 2 Doses 2 Doses 2 Doses 2 Doses 2 Doses
(n = 10) (n = 9) (n = 8) (n = 9) (n = 8) (n = 8) (n = 8)
MedDRA Preferred term n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Subjects with at least one solicited AE 8 (80.0) 9 (100.0) 6 (75.0) 8 (88.9) 7 (87.5) 6 (75.0) 8 (100.0)
Arthralgia – 1 (11.1) 1 (12.5) 1 (11.1) – – 2 (25.0)
Diarrhoea 1 (10.0) 3 (33.3) 1 (12.5) 1 (11.1) 2 (25.0) – –
Fatigue 6 (60.0) 6 (66.7) 2 (25.0) 6 (66.7) 5 (62.5) 4 (50.0) 7 (87.5)
Headache 6 (60.0) 5 (55.6) 2 (25.0) 4 (44.4) 5 (62.5) 5 (62.5) 6 (75.0)
Injection site erythema – 2 (22.2) – – – – 1 (12.5)
Injection site swelling – 1 (11.1) – – 1 (12.5) – 2 (25.0)
Injection site pain 2 (20.0) 8 (88.9) 3 (37.5) 5 (55.6) 6 (75.0) 4 (50.0) 5 (62.5)
Myalgia 4 (40.0) 6 (66.7) 1 (12.5) 5 (55.6) 3 (37.5) 4 (50.0) 5 (62.5)
Pyrexia 2 (20.0) – 2 (25.0) 1 (11.1) 3 (37.5) 1 (12.5) 2 (25.0)
Subjects with at least one unsolicited AE 8 (80.0) 9 (100.0) 7 (87.5) 8 (88.9) 8 (100.0) 6 (75.0) 8 (100.0)
Aspartate aminotransferase increased – 1 (11.1) 1 (12.5) 1 (11.1) 1 (12.5) 2 (25.0) –
Bradycardia – – 2 (25.0) – 3 (37.5) – –
Haemoglobin decreased 2 (20.0) 1 (11.1) – 1 (11.1) 3 (37.5) 1 (12.5) 2 (25.0)
Heart rate decreased 1 (10.0) 1 (11.1) – 3 (33.3) – 2 (25.0) 2 (25.0)
Nausea – 1 (11.1) – – – 1 (12.5) 3 (37.5)
Neutrophil count decreased 2 (20.0) 3 (33.3) 1 (12.5) 3 (33.3) 4 (50.0) 1 (12.5) 3 (37.5)
Pharyngolaryngeal pain – 1 (11.1) – – – – 4 (50.0)
Protein in urine 1 (10.0) 1 (11.1) 1 (12.5) 2 (22.2) 1 (12.5) – 2 (25.0)
Respiratory tract infection 4 (40.0) 2 (22.2) 4 (50.0) 4 (44.4) 4 (50.0) 2 (25.0) 1 (12.5)
Note: Individual unsolicited AEs are shown for AEs reported in P10% of subjects across the combined H4:IC31 regimens. A full list of AEs is presented in Supplementary
Table 2B.
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post-vaccination inflammatory reaction was observed at the TST
injection site in some of the subjects who were screened with
the TSTs at the time of inclusion. Most of these TST reactions were
mild or moderate, although one subject developed a more severe
TST site reaction. Thus, TST screening was removed from the study
protocol and should be omitted from subsequent studies of H4:
IC31. Accordingly, TST was not performed during screening in
another trial testing safety and immunogenicity of H4:IC31 in
BCG-vaccinated adults enrolled in a high-endemic setting in South
Africa (Aeras protocol C-011-404) [18]. The TST reaction mostly
occurred upon vaccination with the H4 antigen alone, which sug-
gested that this local inflammation was caused by the Mtb-
specific antigens and not by the adjuvant. A similar post-
vaccination reaction at the site of skin testing was reported in a
clinical trial with another recombinant protein adjuvant TB vaccine
candidate, M72F/AS02 [23]. This delayed-type hypersensitivity is
likely caused by PPD-specific T cells that will rapidly migrate to
the TST injection site in response to vaccine-antigens that are also
present in PPD. Thus, the risk for post-vaccination TST site reac-
tions needs to be considered upon administration of similar TB
vaccine constructs.
There are no well-defined correlates or biomarkers of protec-
tive immunity in TB, although CD4+ Th1 cells that express IFN-
c, IL-2 and TNF-a are considered necessary [24,25]. Ag85B-
TB10.4 responses may provide the most consistent protection in
populations with a high TB burden [26]. The TB10.4 antigen is
recognized by T cells from both BCG-vaccinated and Mtb-
infected individuals [7], and TB10.4-specific CD4+ T cells corre-
lated with protection against TB in mice [27]. Adoptive transfer
of Ag85B/TB10.4-specific memory CD4+ T cells from immunized
mice also conferred protection against M. bovis BCG challenge in
recipient mice [28]. Likewise, the H4:IC31 vaccine was able to eli-
cit expansion of and cytokine-production in Mtb-specific CD4+ T
cells in BCG-vaccinated adults, similar to the low vaccine-
specific CD4+ T cell responses demonstrated in a related random-
ized trial conducted in South Africa (C-011-404) [18]. Overall, themagnitude and quality of the CD4+ T cell responses induced by
H4:IC31 seemed very similar between the South Africa trial and
the dose-escalation trials conducted in a low-TB-endemic setting
in Sweden and Finland. Both IFN-c ELISpot and ICS results con-
firmed that after two doses of H4:IC31, cytokine producing T cells
were detected primarily in response to the Ag85B component of
H4 [18]. In mice, comparable T cell responses have been detected
against both Ag85B and TB10.4 after vaccination with an Ag85B/
TB10.4 subunit vaccine [8]. Despite the dominance of Ag85B-
specific T cell responses, it is possible that even very low
responses to TB10.4 in H4:IC31 vaccinated individuals could be
expanded upon exposure to Mtb, especially since TB10.4 epitopes
are presented during active TB infection [7].
Multifunctional T cells, co-expressing several cytokines includ-
ing IFN-c, IL-2, and TNF-a, have been associated with immune con-
trol of parasites [28], and viral [29] and bacterial infections [30]. It
has been suggested that the IFN-c/IL-2/TNF-a triple positive cells
represent effector memory T cells, the IL-2/TNF-a double positive
cells central memory cells, and the IFN-c single positive cells ter-
minally differentiated effector T cells [24]. In the experimental
mouse model, the TB subunit vaccine Ag85B-ESAT-6/CAF01 was
shown to induce high levels of multifunctional memory CD4+ T
cells with protective efficacy that accumulated at the site of infec-
tion after Mtb challenge, while fewer multifunctional T cells were
evident upon BCG vaccination [31]. Importantly, two doses of the
Ag85B-ESAT-6/CAF01 subunit vaccine induced long-term memory
responses [22]. The H4:IC31 vaccine induced primarily IFN-c/IL-2/
TNF-a triple positive and IL-2/TNF-a double positive CD4+ Th1
subsets that correlated with protection against subsequent chal-
lenge with Mtb in mice [14,16]. An increased proportion of
TB10.4-specific multifunctional CD4+ T cells were also found at
the site of infection when mice received H4:IC31 as a boost to
the BCG vaccine compared to vaccination with BCG alone [14].
Our observations suggest that the H4:IC31 vaccine induced similar
multifunctional CD4+ T cell profiles in BCG-vaccinated human sub-
jects, which is also consistent with the H4:IC31 trial in South Africa
[18]. Such multifunctional CD4+ T cells were also observed in
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Fig. 2. H4:IC31 vaccination induces elevated levels of antigen-specific CD4+ T cells in the peripheral circulation of BCG-vaccinated study subjects. Frequencies of Ag85B- and
TB10.4-specific CD4+ T cells induced by the H4:IC31 vaccine were measured by 7-color ICS assay and flow cytometry after stimulation of PBMCs with Mtb antigen-peptide
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vaccine [32]. The induction of memory cells by the H4:IC31 vaccine
can be a source of new effector cells that emerge after immune
contraction, which could be particularly important for control of
chronic infections.
These trials clearly show stronger and more persistent antigen-
specific CD4+ T cell responses upon vaccination with the H4 anti-
gen together with the IC31 adjuvant compared to H4 alone. The
IC31 adjuvant has previously been demonstrated to augment sus-
tained Ag85B-ESAT-6 specific IFN-c responses in healthy human
subjects [9]. We also found a clear advantage of two vaccinations
compared to only one dose. In the South Africa trial, the H4:IC31
vaccine containing the 15 lg dose showed a stronger boosting
effect after the second vaccination compared to the 5 and 50 lg
dose levels [18], while a similar discrepancy between the 5, 15
and 50 lg H4 doses was not apparent in our trials. In addition,
one dose was shown to induce post-vaccination IFN-c responsesabove pre-vaccination responses in most of 8 participants in the
South African trial [18], whereas participants receiving only one
dose in our Nordic trials maintained low T cell responses. The
explanation for these differences is unclear, but it is difficult to
make conclusions from these smaller studies (around 8 subjects/
per vaccine regimen), although the results may reflect on the dif-
ferent study populations i.e. Africans from a high-TB-endemic
country who may also become exposed to non-tuberculous
mycobacteria versus northern Europeans from low-TB-endemic
countries who may be more naïve to Mtb as well as environmental
mycobacteria.
Interestingly, an increased H4 antigen dose from 50 lg to
150 lg induced weaker CD4+ T cell responses, which is consistent
with other studies showing that induction of Mtb-specific multi-
functional T cells by Ag85B-TB10.4/IC31 was highly depended on
the H4 antigen dose [16,18]. In contrast to higher antigen doses,
a lower antigen dose selectively increased the number of
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stronger protection against subsequent Mtb challenge in mice
[16]. Therefore, finding the appropriate antigen and adjuvant doses
is a crucial factor when testing new vaccines. Our data suggest that
low range H4 antigen doses in combination with the higher dose of
the IC31 adjuvant would be the optimal vaccine regimen to use in a
larger scale.
Protective immunity in TB is also dependent on the induction of
CD8+ cytolytic T cell (CTL) responses [33]. Using a whole blood
assay (FASCIA), we demonstrated that similar to CD4+ T cell
responses, significant proliferation of Ag85B-stimulated CD8aa+
T cells were seen with the two dose 50/500 H4:IC31 vaccine com-
pared to the two dose placebo regimen. These results were consis-
tent with previous data demonstrating an increased in vitro
proliferation of CD4+ T cells and CD8aa+ T cells in response to
Ag85B, after immunization with the TB vaccine candidate rBCG
AFRO-1 in non-human primates [21]. It is believed that CD8aa+ Tcells comprise effector memory cells and terminally differentiated
memory cells, and persistence of these cells may reflect the pres-
ence of continuous antigen stimulation [34]. IC31 is mostly consid-
ered a CD4+ T cell priming adjuvant that induces activation of
major histocompatibility complex (MHC) class II+ dendritic cells
(DCs) including an up-regulated expression of co-stimulatory
molecules [35]. It has been suggested that adjuvant-activated
DCs may also trigger CD8+ T cells via TLR9-dependent production
of IFNb and enhanced MHC class I antigen presentation [36]. How-
ever, few studies have investigated the effects of the IC31 adjuvant
on the induction of CD8+ T cell responses in vivo and/or in humans
[37], which may be relatively lower compared to CD4+ T cells [14].
To enhance CD8+ T cell activation more efficiently, a pore-forming
protein such as a bacterial cytolysin, e.g. perfringolysin [21,38] or
listeriolysin [39], can be introduced in the vaccine construct to per-
mit leakage of antigens from the phagosome to the cytosolic MHC
class I pathway.
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1660 M. Norrby et al. / Vaccine 35 (2017) 1652–1661Encouraging results from these trials support further clinical
evaluation and development of the H4:IC31 vaccine candidate to
boost protective immunity against TB. In view of that, H4:IC31 is
currently being evaluated for the ability to prevent Mtb infection
in QuantiFERON-negative healthy adults compared to placebo
and BCG revaccination in a randomized controlled trial conducted
in South Africa (Aeras protocol C-040-404 and Clinicaltrial.gov ID:
NCT02075203).Funding
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